News
Sanofi, Orano cue up filings for GEP-NET radioligand therapy
Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.
News
After FDA exit, Peter Marks pops up at Lilly
The ousted former director of CBER, Peter Marks, has joined Eli Lilly as head of molecular discovery and infectious disease research.
News
MSD advances on a broad front with TL1A drug tulisokibart
MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.
News
AZ chalks up another positive trial for hypertension drug
AstraZeneca's baxdrostat has hit the mark in another phase 3 trial in resistant hypertension, keeping it on track for filing later this year.
News
Ignota vacuums up Kronos Bio's drug programmes
Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
